MerckMRK
MRK
0
Funds holding %
of 6,810 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
8% more repeat investments, than reductions
Existing positions increased: 1,497 | Existing positions reduced: 1,389
7% more call options, than puts
Call options by funds: $1.98B | Put options by funds: $1.85B
9% less first-time investments, than exits
New positions opened: 145 | Existing positions closed: 159
2% less funds holding
Funds holding: 3,478 [Q2] → 3,416 (-62) [Q3]
3.03% less ownership
Funds ownership: 79.82% [Q2] → 76.78% (-3.03%) [Q3]
12% less capital invested
Capital invested by funds: $251B [Q2] → $221B (-$29.8B) [Q3]
42% less funds holding in top 10
Funds holding in top 10: 190 [Q2] → 111 (-79) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$105
6%
upside
Avg. target
$118
19%
upside
High target
$130
31%
upside
9 analyst ratings
4 positive
44%
5 neutral
56%
0 negative
0%
UBS Colin Bristow 18% 1-year accuracy 3 / 17 met price target | 21%upside $120 | Buy Maintained | 8 Jan 2025 |
Truist Securities Robyn Karnauskas 14% 1-year accuracy 4 / 28 met price target | 11%upside $110 | Hold Downgraded | 8 Jan 2025 |
BMO Capital Evan David Seigerman 22% 1-year accuracy 4 / 18 met price target | 6%upside $105 | Market Perform Downgraded | 20 Dec 2024 |
B of A Securities Tim Anderson 33% 1-year accuracy 2 / 6 met price target | 22%upside $121 | Buy Reinstated | 10 Dec 2024 |
Guggenheim Seamus Fernandez 58% 1-year accuracy 7 / 12 met price target | 31%upside $130 | Buy Maintained | 6 Nov 2024 |
Financial journalist opinion
Based on 54 articles about MRK published over the past 30 days
Positive
Seeking Alpha
14 hours ago
3 Ideal Buys From 51 'Safer' Dividends In 100 January Barron's Sustainable Dogs
Calvert Research and Management's annual review identified the top 100 sustainable companies based on over 230 ESG performance indicators, including workplace diversity and greenhouse-gas emissions. Eight dividend-paying sustainable companies offer annual dividends from a $1K investment exceeding their single share prices, signaling potential buy opportunities. Analysts forecast net gains of 27.62% to 59.85% for top ESG companies by January 2026, with Regions Financial leading at an estimated 59.84%.
Neutral
Business Wire
1 day ago
Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today announced it will collaborate with Merck as a premier platform to generate RWE, replicate studies and produce rapid insights and analytics on real-world data (RWD). Through this collaboration, Atropos Health will enable rapid cohort creation, advanced analytics and publication-grade studies in less than 48 hours. As part of the agreement.
Positive
CNBC
3 days ago
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.
Neutral
Barrons
3 days ago
There's a ‘Shadow' Over Biotech Stocks. Why It Isn‘t All Bad News.
UBS lowered its price targets for Pfizer, Merck, and Moderna stocks.
Neutral
Investors Business Daily
3 days ago
8 Stocks' Huge Profit Growth Is About To Knock Your Socks Off
Looking for some truly wowing profit growth from S&P 500 companies. A few are likely to knock your socks off.
Positive
24/7 Wall Street
3 days ago
Merck Just Paid Investors: How Much Did They Receive?
Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable on Wednesday, Jan.
Neutral
Business Wire
3 days ago
Merck's GARDASIL® Receives Expanded Approval for Males in China
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's GARDASIL® Receives Expanded Approval for Males in China.
Positive
Reuters
3 days ago
Merck says its HPV vaccine for men was approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration.
Neutral
Zacks Investment Research
5 days ago
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) closed at $99.72 in the latest trading session, marking a +0.59% move from the prior day.
Positive
Reuters
5 days ago
China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million.
Charts implemented using Lightweight Charts™